Huntington's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old
- You are willing and able to sign a consent form agreeing to take part in the study
- You have been found to carry a specific genetic change (a CAG repeat number of 36 or more) that is linked to Huntington's disease, whether or not you currently have symptoms
- You are covered by a social security or health insurance scheme (this applies mainly to participants in France)
Who may not be able to join:
- You have previously taken part in a gene therapy trial that involved treatments designed to affect how the Huntingtin gene works — such as AAV-based therapies, ASO treatments, or similar approaches (confirm with trial site if you are unsure whether a past trial counts)
- There are signs or test results suggesting your condition may have a different cause or diagnosis than Huntington's disease
- You are not able to give your own consent to participate
- You are currently pregnant, breastfeeding, or in labour
- You are currently under a court or administrative order that restricts your freedom (such as being detained)
- You are under a legal protection arrangement, such as being under guardianship or curatorship
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: VERNY Christophe, MD, PhD, University Hospital, Angers
Phone: 02.41.35.56.15
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
In vitro validation of a RNA trans-splicing gene therapy for the correction of supernumerary CAG repeats into fibroblasts derived from skin biopsies of patients with Huntington's disease.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.